Richard G Everson1, Yuuri Hashimoto1, Jacob L Freeman1, Tiffany R Hodges1, Jason Huse2, Shouhao Zhou3, Joanne Xiu4, David Spetzler4, Nader Sanai5, Lyndon Kim6, Santosh Kesari7, Andrew Brenner8, Franco De Monte1, Amy Heimberger9, Shaan M Raza1. 1. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Caris Life Sciences, Phoenix, AZ, USA. 5. Division of Neurosurgical Oncology, Barrow Neurological Institute, Phoenix, AZ, USA. 6. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA. 7. John Wayne Cancer Institute at Providence, Santa Monica, CA, USA. 8. Cancer Treatment Research Center, University of Texas Health Science Center, San Antonio, TX, USA. 9. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. aheimber@mdanderson.org.
Abstract
INTRODUCTION: Surgery and radiation therapy are the standard treatment options for meningiomas, but these treatments are not always feasible. Expression profiling was performed to determine the presence of therapeutic actionable biomarkers for prioritization and selection of agents. METHODS: Meningiomas (n = 115) were profiled using a variety of strategies including next-generation sequencing (592-gene panel: n = 14; 47-gene panel: n = 94), immunohistochemistry (n = 8-110), and fluorescent and chromogenic in situ hybridization (n = 5-70) to determine mutational and expression status. RESULTS: The median age of patients in the cohort was 60 years, with a range spanning 6-90 years; 52% were female. The most frequently expressed protein markers were EGFR (93%; n = 44), followed by PTEN (77%; n = 110), BCRP (75%; n = 8), MRP1 (65%, n = 23), PGP (62%; n = 84), and MGMT (55%; n = 97). The most frequent mutation among all meningioma grades occurred in the NF2 gene at 85% (11/13). Recurring mutations in SMO and AKT1 were also occasionally detected. PD-L1 was expressed in 25% of grade III cases (2/8) but not in grade I or II tumors. PD-1 + T cells were present in 46% (24/52) of meningiomas. TOP2A and thymidylate synthase expression increased with grade (I = 5%, II = 22%, III = 62% and I = 5%, II = 23%, III = 47%, respectively), whereas progesterone receptor expression decreased with grade (I = 79%, II = 41%, III = 29%). CONCLUSION: If predicated on tumor expression, our data suggest that therapeutics directed toward NF2 and TOP2A could be considered for most meningioma patients.
INTRODUCTION: Surgery and radiation therapy are the standard treatment options for meningiomas, but these treatments are not always feasible. Expression profiling was performed to determine the presence of therapeutic actionable biomarkers for prioritization and selection of agents. METHODS:Meningiomas (n = 115) were profiled using a variety of strategies including next-generation sequencing (592-gene panel: n = 14; 47-gene panel: n = 94), immunohistochemistry (n = 8-110), and fluorescent and chromogenic in situ hybridization (n = 5-70) to determine mutational and expression status. RESULTS: The median age of patients in the cohort was 60 years, with a range spanning 6-90 years; 52% were female. The most frequently expressed protein markers were EGFR (93%; n = 44), followed by PTEN (77%; n = 110), BCRP (75%; n = 8), MRP1 (65%, n = 23), PGP (62%; n = 84), and MGMT (55%; n = 97). The most frequent mutation among all meningioma grades occurred in the NF2 gene at 85% (11/13). Recurring mutations in SMO and AKT1 were also occasionally detected. PD-L1 was expressed in 25% of grade III cases (2/8) but not in grade I or II tumors. PD-1 + T cells were present in 46% (24/52) of meningiomas. TOP2A and thymidylate synthase expression increased with grade (I = 5%, II = 22%, III = 62% and I = 5%, II = 23%, III = 47%, respectively), whereas progesterone receptor expression decreased with grade (I = 79%, II = 41%, III = 29%). CONCLUSION: If predicated on tumor expression, our data suggest that therapeutics directed toward NF2 and TOP2A could be considered for most meningiomapatients.
Authors: Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter Journal: Sci Transl Med Date: 2014-05-21 Impact factor: 17.956
Authors: Matthew R Strickland; Corey M Gill; Naema Nayyar; Megan R D'Andrea; Christian Thiede; Tareq A Juratli; Gabriele Schackert; Darrell R Borger; Sandro Santagata; Matthew P Frosch; Daniel P Cahill; Priscilla K Brastianos; Fred G Barker Journal: J Neurosurg Date: 2016-11-25 Impact factor: 5.115
Authors: Andrew D Norden; Keith L Ligon; Samantha N Hammond; Alona Muzikansky; David A Reardon; Thomas J Kaley; Tracy T Batchelor; Scott R Plotkin; Jeffrey J Raizer; Eric T Wong; Jan Drappatz; Glenn J Lesser; Sam Haidar; Rameen Beroukhim; Eudocia Q Lee; Lisa Doherty; Debra Lafrankie; Sarah C Gaffey; Mary Gerard; Katrina H Smith; Christine McCluskey; Surasak Phuphanich; Patrick Y Wen Journal: Neurology Date: 2014-12-19 Impact factor: 9.910
Authors: Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados Journal: Neuro Oncol Date: 2009-12 Impact factor: 12.300
Authors: Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock Journal: Clin Cancer Res Date: 2012-09-10 Impact factor: 12.531
Authors: Tiffany R Hodges; Martina Ott; Joanne Xiu; Zoran Gatalica; Jeff Swensen; Shouhao Zhou; Jason T Huse; John de Groot; Shulin Li; Willem W Overwijk; David Spetzler; Amy B Heimberger Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Jacky Yeung; Vesal Yaghoobi; Danielle Miyagishima; Matthew D Vesely; Tianxiang Zhang; Ti Badri; Ala Nassar; Xue Han; Miguel F Sanmamed; Mark Youngblood; Matthieu Peyre; Michel Kalamarides; David L Rimm; Murat Gunel; Lieping Chen Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 12.300
Authors: Anna S Berghoff; Thomas Hielscher; Gerda Ricken; Julia Furtner; Daniel Schrimpf; Georg Widhalm; Ursula Rajky; Christine Marosi; Johannes A Hainfellner; Andreas von Deimling; Felix Sahm; Matthias Preusser Journal: Brain Pathol Date: 2022-03 Impact factor: 6.508
Authors: Priscilla K Brastianos; Albert E Kim; Anita Giobbie-Hurder; Eudocia Quant Lee; Nancy Wang; April F Eichler; Ugonma Chukwueke; Deborah A Forst; Isabel C Arrillaga-Romany; Jorg Dietrich; Zachary Corbin; Jennifer Moliterno; Joachim Baehring; Michael White; Kevin W Lou; Juliana Larson; Magali A de Sauvage; Kathryn Evancic; Joana Mora; Naema Nayyar; Jay Loeffler; Kevin Oh; Helen A Shih; William T Curry; Daniel P Cahill; Fred G Barker; Elizabeth R Gerstner; Sandro Santagata Journal: Nat Commun Date: 2022-03-14 Impact factor: 14.919
Authors: Michelle A Wedemeyer; Ivo Muskens; Ben A Strickland; Oscar Aurelio; Vahan Martirosian; Joseph L Wiemels; Daniel J Weisenberger; Kai Wang; Debraj Mukerjee; Suhn K Rhie; Gabriel Zada Journal: Neurooncol Adv Date: 2022-06-06